Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.
about
Insomnia pharmacotherapyNovel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexantAdvances in the management of insomniaSuvorexant for the treatment of insomnia.Quality measures for the care of patients with insomnia.Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study.Gender Differences in the Efficacy and Safety of Chronic Nightly Zolpidem.Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial.Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future HorizonsHyperarousal in insomnia and hypnotic dose escalation.Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis usersOrexin OX2 Receptor Antagonists as Sleep Aids.Is suvorexant a better choice than alternative hypnotics?Patterns of zolpidem use among Iraq and Afghanistan veterans: A retrospective cohort analysis.The effects of repeated zolpidem treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile expression in mice: comparison with diazepam.
P2860
Q24623757-C5B0A621-5FE3-45AF-97B3-A5D3E53F7E6EQ26740978-7D975317-7122-4522-8C0A-40976F248991Q33720437-C4069DE3-57C1-411D-93C4-FEC60D89AF73Q34443676-F50B7CA5-E2F8-49D0-A17B-F8CF596AA484Q35138196-78AC361F-9058-49B0-A864-4CAF50E1F56EQ36304821-63B58EE5-EEB2-4B41-96E3-9250B9A357B1Q36637811-3B5579AF-494E-47AA-BB06-5D67B00BEB48Q36651723-7C01F1C5-16D2-4D71-AA61-1DC6BC5B4740Q37149325-871D7FA1-904F-426D-9B75-7D0AE6933029Q37337535-4B82F69A-D8ED-4146-B222-5D2E59BE7506Q37635636-5142726C-9140-47B4-ADFA-5401DBE755D6Q39026714-7972DFF0-038C-44AC-A5B6-C92FBD8F6FA6Q40900071-D0910D45-5169-4F1F-AB05-5BAF1E613B7EQ47642021-92E86B62-F04A-4B8A-A39A-C8844F769434Q47798865-3912AF96-83D2-4B74-900D-AE69EF24AB3D
P2860
Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 October 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Twelve months of nightly zolpi ...... tive placebo-controlled study.
@en
Twelve months of nightly zolpi ...... tive placebo-controlled study.
@nl
type
label
Twelve months of nightly zolpi ...... tive placebo-controlled study.
@en
Twelve months of nightly zolpi ...... tive placebo-controlled study.
@nl
prefLabel
Twelve months of nightly zolpi ...... tive placebo-controlled study.
@en
Twelve months of nightly zolpi ...... tive placebo-controlled study.
@nl
P2093
P2860
P356
P1476
Twelve months of nightly zolpi ...... tive placebo-controlled study.
@en
P2093
P2860
P304
P356
10.1177/0269881111424455
P407
P577
2011-10-16T00:00:00Z